Support and Resistance Levels
Past performance
About Aurobindo Pharma Ltd Aurobindo Pharma Limited (APL), founded in 1986, is a prominent global pharmaceutical company specializing in active pharmaceutical ingredients (APIs) and generic formulations across six major product areas, including antibiotics and anti-retrovirals. With 24 manufacturing plants and nine R&D facilities worldwide, APL's products are approved by the World Health Organization and are marketed in over 150 countries. The company has an extensive portfolio with around 65 non-antibiotic and over 55 antibiotic APIs.
Strategic acquisitions and joint ventures have bolstered APL’s international presence, including partnerships with Glaxo, AstraZeneca, and the establishment of ventures in the US, China, and Russia. APL has expanded its product range significantly, with 337 Drug Master Files filed globally. Recent activities include acquiring biosimilars, nutraceutical brands, and oncology businesses. Aurobindo continues to innovate in the biosimilar and vaccine space, demonstrating a commitment to expanding its pharmaceutical footprint and product offerings in regulated and emerging markets.